#highlight n•1 💫 The presence of specific peripheral blood T cell sub-populations associated w/ disease flares in RA pts in remission after cs or bioDMARDs tapering or cessation identified in 2 different abstracts OP0011 and OP0074 @RheumNow #EULAR2022 https://t.co/SO2AgtkyTP

Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD

#EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study ⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction ⭐️CV safety non-inferior to allopurinol @Rheumnow https://t.co/1oDSioQWPT

Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue

We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go… because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander. Understanding TNFi resistance is path to: predicting it knowing best what to do with it @RheumNow https://t.co/22Y6iinSbH

Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls. (miRNAs: non-coding RNAs controlling gene expression) PsO/PsA miRNAs involved in bone metabolism @RheumNow #EULAR2022 ABST#POS0314

#EULAR2022 POS0283: Do Rheums have Gout Stigma? ⭐️Stereotypes about pt related factors ⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA @Rheumnow

Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L

• EULAR Abstract Archive

PMR on the podium @profbdasgupta, with a positive phase 3! Sarilumab in relapsing PMR (SAPHYR): sari q2w+14w taper vs placebo+52w taper underrecruited 118/280 (COVID) but still hit primary, almost all secondary Better outcome + steroid-sparing: big LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0

#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP

Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa

#EULAR2022 LB0005 Orelabrutinib- BTKi- for SLE, PIb/IIa ⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4 ⭐️Improved proteinuria @Rheumnow https://t.co/bmREhmL7sq

SAPHYR trial of sarilumab for relapsing PMR @profbdasgupta et al. Sarilumab+14 week steroids vs 52 week steroid monotherapy. Sustained remission 28.3% vs 10.3% P=0.0193. Flare after remission 16.7% vs 29.3% HR 0.56 (0.35–0.90) P=0.0158 @RheumNow #EULAR2022 https://t.co/oopWKjciWG https://t.co/xi4ELJiCXa

• EULAR Abstract Archive

Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV